LUIS DIAZ: Open Payments
NPI 1245677426 · LATHAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,125 in 88 payments from 21 companies in 2025. Trend: 2023 $1,359 · 2024 $1,637 · 2025 $2,125
Food & beverage: $2,125
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $469 |
| Lilly USA, LLC | 11 | $332 |
| AstraZeneca Pharmaceuticals LP | 7 | $264 |
| Abbott Laboratories | 6 | $208 |
| Novo Nordisk Inc | 8 | $170 |
| GlaxoSmithKline, LLC. | 6 | $131 |
| SANOFI-AVENTIS U.S. LLC | 2 | $81 |
| Astellas Pharma US Inc | 3 | $75 |
| Amgen Inc. | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
Products named: ZEPBOUND, FREESTYLE LIBRE 3, QULIPTA, VRAYLAR, UBRELVY, BREZTRI, AIRSUPRA, Ozempic.
Industry payments across NY — which companies pay providers there.
